Alternative protein: what are the top startups?
In our alternative protein market deck, you will find everything you need to understand the market
SUMMARY
The EVERY Company is the strongest alternative protein startup today, with Heura, Vow, PARIMA and Impossible Foods forming the next group for very different reasons.
The leaderboard has changed because historical fundraising is no longer a good shortcut for operating strength. Several heavily funded companies have restructured, shut down or entered insolvency after proving that large facilities and technical milestones do not automatically create a durable food business.
Fermentation is pulling ahead because it currently offers the cleanest path from technical progress to commercial use. Ingredients such as egg proteins and casein can plug into products manufacturers already know how to make, without requiring consumers to adopt an entirely new eating habit.
EVERY stands out because the commercial chain is unusually complete: order volume accelerated, capacity became insufficient, Huvepharma expanded production and ADM joined as another manufacturing partner. That is stronger proof than a large funding round on its own.
Heura is interesting for almost the opposite reason. Plant-based meat is a mature and shrinking category in several markets, so reaching positive EBITDA while concentrating on stronger geographies says more than another headline growth target would.
Cultivated meat is finally producing more meaningful industrial evidence. Vow has multi-country sales and repeated restaurant distribution, while PARIMA’s recent multi-tonne 22,000-liter run shows that production scale is moving beyond the pilot stage faster than it was a few years ago.
The most credible cultivated-meat strategies are also becoming more selective. Mission Barns is using cultivated fat inside hybrid products, while Wildtype is starting with premium salmon, where higher selling prices give the economics more room to work.
Manufacturing strategy now matters almost as much as the biology. EVERY, Onego, Standing Ovation and New Culture all lean on established industrial partners instead of assuming that every startup needs to build a giant proprietary factory.
The fastest-rising companies are generally raising money for commercialization, capacity or production efficiency rather than another long R&D cycle. Plantible, PARIMA, Planetary, MAASH and Millow all fit that pattern to different degrees.
The clearest dividing line in alternative protein today is not plant-based versus fermentation versus cultivated meat. It is whether a company can connect technical progress to repeat demand, practical manufacturing and a financing model that does not outrun the business.
That is why the strongest startups today often look narrower and more operational than the sector’s earlier champions. The companies moving up are selling specific ingredients, focusing on chosen markets and scaling only when the next commercial step is visible.
This market map, featured in our alternative protein market deck, highlights top companies and startups in the alternative protein market
What counts as a top alternative protein startup today?
The top alternative protein startups today are the companies that have turned difficult food technology into something customers can buy, manufacturers can produce repeatedly, and investors can still finance.
A few years ago, cumulative funding could almost stand in for leadership. That shortcut has aged badly. Meati raised roughly $400 million before its previous corporate entity went through an assignment-for-the-benefit-of-creditors process. Believer Meats built a large cultivated-meat facility in North Carolina and later entered insolvency proceedings. Several other cultivated-meat companies disappeared after raising tens or hundreds of millions of dollars.
The market has also split into three very different races. Plant-based startups already know how to manufacture food at scale, so we care much more about sales velocity, margins and repeat consumption. Precision-fermentation companies have to prove that fermentation yields and manufacturing costs work outside pilot tanks. Cultivated-meat companies are earlier still, which makes regulatory approval, large production runs and actual restaurant sales unusually meaningful.
Funding data shows how selective the sector has become. The Good Food Institute's current investment tracker puts alternative-protein investment at $881 million in 2025 and $359 million in the first half of 2026. More tellingly, fermentation attracted $132 million in Q2 2026, compared with $41 million for plant-based companies and $25 million for cultivated meat and seafood.
So our ranking gives far more weight to current commercial proof than to historical hype. A company with a working product, repeat orders and an industrial partner can now rank above a company that raised twice as much money.
| What we care about | What good evidence looks like now |
|---|---|
| Demand | Repeat orders, strong product velocity, real restaurant or retail sales |
| Manufacturing | Large production runs, contracted industrial capacity, falling unit costs |
| Regulation | FDA, SFA, FSANZ or equivalent clearance that enables actual sales |
| Economics | Positive EBITDA, credible cost reductions, less capital-intensive scaling |
| Financing | Capital tied to commercialization rather than another long R&D cycle |
If you want more recent data on this point, please see our latest alternative protein market report.
Why is fermentation pulling ahead in alternative protein?
Fermentation is currently the strongest part of alternative protein because it is producing the best mix of customer demand, industrial scale-up and fresh financing.
We can see it directly in the money. GFI's latest quarterly breakdown shows fermentation taking roughly two-thirds of Q2 alternative-protein funding. Our own review of the latest disclosed rounds points in the same direction: nine of the 12 most recent financings we tracked involved fermentation, including Standing Ovation, Planetary, Those Vegan Cowboys, StrainX Bioworks and Pacifico Biolabs.
The companies receiving money have also changed. Standing Ovation raised $34.2 million to commercialize precision-fermented casein after validating industrial production with Bel Group. Planetary secured roughly $28 million in equity and credit to expand fermentation infrastructure and its licensing model. Pacifico Biolabs raised about $8 million to put mycelium production into underused brewery infrastructure. More recently, MAASH secured €12.15 million to move mycoprotein production toward industrial scale.
Food manufacturers understand these products more easily than many early consumer meat substitutes. EVERY sells egg-white functionality. Standing Ovation sells casein. Onego Bio sells ovalbumin. These ingredients already perform useful jobs inside bakeries, cheeses, confectionery and prepared foods.
That is why fermentation looks much stronger today. Companies can sell better performance, a more stable supply chain or a useful industrial ingredient without asking consumers to completely rethink what dinner should look like.
As this chart shows, and as featured in our alternative protein market deck, search interest in pea protein has been growing steadily
Is The EVERY Company the strongest alternative protein startup right now?
The EVERY Company is the strongest alternative protein startup in our ranking right now.
The clearest evidence came when EVERY disclosed that annual OvoPro orders secured during the first four months of 2026 were already worth more than 550% of its entire 2025 order volume. That number came with an expensive consequence: the company had to quadruple production capacity with Huvepharma.
The manufacturing side is unusually convincing. Huvepharma's Biovet operation has more than nine million liters of installed fermentation capacity in Bulgaria, and EVERY is already producing at commercial scale there. Then, in July 2026, ADM agreed to manufacture OvoPro at its Clinton, Iowa complex, giving EVERY its first U.S. production site and another route to much larger volumes.
The product has also escaped the food-tech bubble. Ingredients made by EVERY are already appearing in products sold through Walmart, Target and Amazon. The company is selling a functional ovalbumin protein that can bind, gel, foam and add protein in many of the applications where manufacturers currently use egg whites.
We still lack detailed revenue, gross-margin and customer-concentration figures, so EVERY has not answered every economic question. But the sequence is hard to ignore: customers ordered much more product, existing capacity became insufficient, Huvepharma expanded production and ADM then joined as another manufacturing partner.
That is the kind of problem an alternative-protein startup wants to have.
If you want more recent data on this point, please see our latest alternative protein market report.
Can Heura keep winning while plant-based meat is shrinking?
Heura currently looks like the strongest pure plant-based meat startup because it has reached profitability while taking share in a weak category.
The Spanish market gives us a useful stress test. Nielsen data cited by Heura showed Spain's meat-alternative category contracting in 2025. Heura still reached its highest market share, and its two flagship plant-based beef burgers generated 39% of sales across a Spanish burger assortment containing 133 SKUs.
That concentration is remarkable. Two products were effectively taking about two-fifths of a category crowded with more than a hundred alternatives. Heura says revenue per burger SKU was 41 times the category average.
Then came the number that changes how we evaluate the company: Heura reached positive EBITDA in Q1 2026. Revenue appears to have fallen as the company deliberately pulled back from weaker Northern European markets, but losses fell much faster. The company chose a smaller profitable footprint over chasing growth everywhere.
Heura has since started opening its production platform to retailers and brands in markets where it does not compete directly. It also recently expanded beyond meat replicas with high-protein vegetable and legume burgers, giving the brand another way to reach consumers who do not regularly buy meat analogues.
Heura may not be a high-growth company anymore. The stronger point is that, among plant-based meat startups, it now has one of the clearest cases that a financially sane business can still be built.
This chart, featured in our alternative protein market deck, shows annual venture capital investment in alternative protein startups
Is Impossible Foods still one of the top alternative protein startups?
Impossible Foods still belongs near the top of the alternative protein market, although its lead is much less obvious today.
Impossible has an installed commercial footprint that younger startups cannot match. The company says around 90% of its U.S. consumers eat meat, and its beef remains one of the fastest-selling products in the U.S. plant-based beef category. Impossible also holds the number-two U.S. plant-based meat market-share position according to its latest corporate disclosures.
Scale helps, but the context has become harder. U.S. plant-based meat and seafood retail sales have been falling, and Impossible has not published the kind of current growth numbers that would put it alongside EVERY's order acceleration or Heura's profitability story.
There has also been a leadership reset. Peter McGuinness left the CEO role in early 2026, after which a three-person executive team took over operating responsibilities. For a company that has raised roughly $2 billion over its lifetime, the bar is understandably much higher than it is for an early-stage fermentation startup.
Impossible therefore stays high in our ranking because distribution, consumer recognition and product velocity still count for a lot. Its current trajectory is simply less compelling than the companies moving from technical validation into rapid commercial scale.
Who is winning animal-free dairy: Formo, Standing Ovation or New Culture?
Formo is currently the most commercially advanced animal-free dairy startup, while Standing Ovation has the strongest recent industrial backing and New Culture has built the most focused casein product.
Formo made a clever sequencing decision. Rather than waiting for precision-fermented casein to be ready at scale, it launched cheeses using koji-based microfermentation and put them into retailers such as REWE and METRO in Germany and Austria. That gave Formo a real commercial business while its more technically difficult precision-fermentation program continued.
The European Investment Bank then provided a €35 million venture-debt facility to help Formo expand production and continue developing animal-free dairy and egg products. Together with earlier equity financing, that pushed Formo's total financing above €135 million.
Standing Ovation has moved faster on industrial casein. The French startup has already validated production with Bel Group and raised $34.2 million in 2026. Danone Ventures joined Bel as a shareholder in that round, giving Standing Ovation strategic backing from two of Europe's biggest dairy groups. Its process is also unusual because it can use whey permeate, a dairy side stream, as feedstock for producing casein.
New Culture is narrower and, in some ways, more interesting technically. It is building animal-free mozzarella around precision-fermented alpha-S1 casein. The company says it has secured roughly $5 million in early demand, works with pizzerias including Nancy Silverton's Pizzeria Mozza, and recently received another U.S. patent specifically covering mozzarella made with its animal-free casein. New Culture also says it has reduced the casein required in its mozzarella by 28%, which attacks the ingredient's biggest cost problem directly.
We keep New Culture below Formo and Standing Ovation for now because production is still the missing proof. New Culture acknowledged in July 2026 that it had yet to reach mass-market manufacturing scale. The product looks strong; the manufacturing needs to catch up.
| Startup | Best current proof | Biggest question left |
|---|---|---|
| Formo | Products already in mainstream European retail | Can precision-fermented casein scale alongside the existing business? |
| Standing Ovation | Industrial validation plus Bel and Danone backing | How quickly can commercial sales follow? |
| New Culture | Strong casein IP, mozzarella performance and early demand | Can it manufacture enough casein cheaply? |
If you want more recent data on this point, please see our latest alternative protein market report.
This chart, featured in our alternative protein market deck, looks at Impossible Foods’ strategy in alternative protein
Can Onego Bio catch The EVERY Company in animal-free egg protein?
Onego Bio is the most credible challenger to EVERY in animal-free egg protein, but EVERY is clearly ahead commercially today.
Onego's Bioalbumen is ovalbumin produced with Trichoderma reesei through precision fermentation. The FDA issued a "no questions" letter for the company's GRAS notice in 2025, opening a wide range of food applications in the United States.
The manufacturing evidence is already beyond lab scale. Onego has reported successful demonstration runs in 62,000-liter vessels with a co-manufacturing partner. It has also completed commercial bakery runs involving thousands of cookies, muffins and cakes, and the company has been sending samples to large food manufacturers.
Onego then added Sigma Foods as a commercial collaboration partner in March 2026. The goal is straightforward: give manufacturers another source of egg protein when conventional egg supply and prices become volatile.
The remaining gap with EVERY is demand at scale. EVERY has already had to expand factories because orders jumped. Onego is still converting technical validation, FDA clearance and customer trials into that same kind of repeat commercial pull.
Onego belongs comfortably inside the top ten, with a realistic path much higher if those customer trials turn into large orders.
Who is actually ahead in cultivated meat today: Vow or PARIMA?
Vow is still the strongest cultivated-meat startup commercially, while PARIMA has recently produced the most striking evidence that large-scale cultivated production may actually work.
Vow has something very few cultivated-meat companies can show: repeated sales across more than one country. Its cultivated Japanese quail products have been approved in Singapore, Australia and New Zealand, and they are already served in restaurants.
The Australian Department of Industry recently reported that demand for Vow's products had risen by roughly 200% per month since its Australian launch. GFI's latest cultivated-meat report also describes Vow's Sydney facility as the largest current cultivated-meat facility, with production at roughly 20,000-liter scale and 35,000 liters of total installed capacity.
Vow has nevertheless gone through a recent restructuring. Founder George Peppou moved out of the CEO role, jobs were cut, and the company is exploring applications for its cell-culture technology beyond food. That does not mean its food business has failed, but it does add a financial and strategic question that was not there before.
PARIMA has suddenly become the company we would watch most closely. Created when Gourmey acquired Vital Meat in 2025, PARIMA now has cultivated chicken and duck programs, regulatory approvals for both species in Singapore, and additional applications moving through other markets.
Then came the production result that changed its position. In July 2026, PARIMA ran its cultivated duck process on Vow's 22,000-liter production line and reported a multi-tonne harvest from a single run. The company also says production cost was 99% lower than earlier runs. Those economics are company-reported and still need commercial validation, but the physical scale is large enough to take seriously.
Vow currently wins on actual market presence. PARIMA is now a very close second because the scale gap that once looked almost theoretical is shrinking much faster than expected.
| Startup | Strongest proof today | Our read |
|---|---|---|
| Vow | Multi-country sales, 20,000-liter-scale production, rapidly growing restaurant demand | Strongest cultivated-meat business today |
| PARIMA | Two species approved in Singapore and a multi-tonne 22,000-liter run | Fastest-rising cultivated-meat challenger |
| Mission Barns | U.S. cultivated pork-fat clearance and consumer sales | Smartest hybrid-product strategy |
| Wildtype | FDA-cleared cultivated salmon sold in several restaurants | Clear cultivated-seafood leader |
| Mosa Meat | Fresh financing and major claimed cost reductions | Technically credible, commercialization still behind leaders |
If you want more recent data on this point, please see our latest alternative protein market report.
This chart, featured in our alternative protein market deck, shows annual funding in alternative protein startups
Is Mission Barns' cultivated fat strategy actually more realistic than whole meat?
Mission Barns has one of the most realistic cultivated-meat strategies because growing only the fat lets a small amount of cultivated material change the taste of a much cheaper finished product.
The company grows pork fat cells and blends them with plant-based ingredients in foods such as meatballs and bacon. The FDA completed its pre-market consultation for Mission Barns' cultivated pork fat, and the product subsequently cleared the additional USDA steps needed for commercial sale.
Mission Barns has since put cultivated pork products in front of paying or prospective retail consumers through restaurant service and grocery-store events in California. The volumes remain tiny compared with conventional pork, but the company has crossed the regulatory and consumer thresholds that stop most cultivated-meat startups long before commercialization.
The hybrid approach also changes the economics. Mission Barns does not need every gram in a meatball to come from a bioreactor. Cultivated fat supplies much of the animal flavor and mouthfeel, while plant proteins provide cheaper mass.
That looks increasingly sensible. If cultivated meat reaches meaningful volume during this decade, hybrid products may get there before a fully cultivated steak.
Is Wildtype turning cultivated salmon into a real business?
Wildtype has made cultivated seafood commercially real, although production volume is still small enough that we cannot call it a scaled business yet.
The FDA completed Wildtype's cultivated coho salmon consultation in 2025, making it the first cultivated seafood product to clear that process in the United States. Wildtype then started serving the salmon at Kann in Portland and expanded to additional restaurants.
The rollout has kept moving. Wildtype added José Andrés's barmini in Washington in June 2026, and the company has used a direct-to-consumer campaign to test interest in cultivated salmon lox. That gives us a broader set of demand experiments than a one-night chef tasting.
Seafood is also a useful starting category. Premium salmon already sells at prices that give Wildtype more room than a company trying to compete immediately with cheap chicken, and seafood falls under FDA oversight rather than the joint FDA-USDA path used for cultivated livestock and poultry.
We still need production-cost and volume data before moving Wildtype into the very top group. For cultivated seafood specifically, though, nobody else currently has comparable regulatory and restaurant proof in the U.S.
This chart, featured in our alternative protein market deck, compares the main business model options for alternative protein brands
Which alternative protein startups are closest to true manufacturing scale?
EVERY, Plantible, Vow, PARIMA and Onego currently give us the strongest manufacturing evidence, but they are reaching scale in very different ways.
EVERY is leaning heavily on existing fermentation giants. That has allowed it to expand with Huvepharma and ADM without spending years building every tank itself. Onego is taking a similar co-manufacturing route and has already run Bioalbumen in 62,000-liter vessels.
Plantible recently made one of the biggest jumps in our ranking. The company secured a new USDA-backed loan alongside equity financing and said the money will quintuple annual Rubi Protein production capacity to more than 1,000 metric tons. Rubi is extracted from lemna, a fast-growing aquatic plant, so Plantible's manufacturing problem looks very different from precision fermentation, but the target volume moves it firmly into industrial ingredient territory.
Cultivated meat works at a much smaller baseline. Vow's facility can run around 20,000 liters, while PARIMA has now demonstrated its own duck process on Vow's 22,000-liter line. A multi-tonne cultivated-meat run remains tiny beside conventional meat processing, yet it is a large jump from the pilot vessels that dominated this sector only a few years ago.
The most interesting pattern is how often the leaders are avoiding giant proprietary factories. EVERY uses Huvepharma and ADM. Onego uses co-manufacturing. Standing Ovation works with industrial partners. New Culture works with CJ CheilJedang and other manufacturers. Capital efficiency has become part of the technology strategy.
| Startup | Manufacturing proof | Where it stands |
|---|---|---|
| The EVERY Company | Commercial production plus Huvepharma and ADM scale-up | Strongest fermentation scale story |
| Plantible | Capacity expansion toward 1,000+ metric tons per year | Strongest plant-derived ingredient scale-up |
| Onego Bio | Successful 62,000-liter demonstration runs | Close to large commercial fermentation |
| Vow | Roughly 20,000-liter-scale cultivated production | Largest established cultivated facility |
| PARIMA | Multi-tonne cultivated duck run at 22,000 liters | Biggest recent cultivated production jump |
Why have so many famous alternative protein startups fallen out of the top tier?
Several famous alternative protein startups have fallen out of the top tier because manufacturing food consumed cash much faster than demand grew.
Meati is the clearest warning. The mycelium-meat company raised roughly $400 million and built substantial manufacturing capacity, yet its previous corporate entity ultimately entered an assignment-for-the-benefit-of-creditors process. A highly funded technology and national retail distribution did not protect the business from weak economics.
Cultivated meat produced an even harsher set of examples. Believer Meats raised hundreds of millions of dollars and built a roughly 200,000-square-foot facility in North Carolina before insolvency proceedings. Meatable shut down after raising more than $100 million. SCiFi Foods and New Age Eats had already disappeared earlier.
GOOD Meat deserves credit for making the world's first commercial cultivated-meat sale, but parent company Eat Just has also spent years dealing with financing pressure and major supplier disputes. Commercial firsts alone no longer guarantee a place near the top of our ranking.
The lesson has changed how we read the surviving companies. We pay close attention when EVERY adds production after orders grow, when Heura gets to positive EBITDA, or when Standing Ovation uses established fermentation manufacturers. Those companies are trying to match capital spending to demand.
The sector can still produce big winners. It has simply become much harder to hide weak economics behind a large fundraising total.
This chart, featured in our alternative protein market deck, shows revenue breakdown by customer segment in the alternative protein market
Which alternative protein startups are moving up fastest right now?
Plantible, PARIMA, Planetary, MAASH and Millow are the alternative protein startups whose position has improved most sharply lately.
Plantible made the biggest immediate move. Its recent financing combines debt and equity and is intended to push Rubi Protein capacity above 1,000 metric tons annually. If that expansion arrives with real customer utilization, Plantible could move much higher than its current position.
PARIMA has moved even faster technically. The combination of Gourmey and Vital Meat gave it two species, a broader regulatory portfolio and more infrastructure. The recent multi-tonne cultivated duck run with Vow now gives the merged company a production result that most cultivated-meat startups cannot match.
Planetary is becoming interesting for a different reason. The Swiss company raised roughly $28 million in 2026 and is building a business around fermentation production, ingredients and process licensing. That gives it several ways to benefit if food companies want fermentation capacity without building their own facilities.
The newest names are still too early for our main ranking. MAASH recently secured €12.15 million to industrialize mycoprotein production. Swedish startup Millow raised €2 million and is preparing to launch its oat-and-mycelium meat in Nordic foodservice. Pacifico Biolabs is also repurposing brewery infrastructure for mycelium production after an approximately $8 million Series A.
None of those companies has enough commercial evidence yet to displace EVERY, Heura or the cultivated-meat leaders. They are worth tracking because today's funding is increasingly going toward factories, production efficiency and market launch rather than another round of basic technical proof.
So, what are the top alternative protein startups today?
The EVERY Company is the strongest alternative protein startup today, with Heura, Vow, PARIMA and Impossible Foods forming the next group for very different reasons.
EVERY gets our number-one spot because the chain of evidence is unusually complete: demand rose sharply, capacity became insufficient, a major fermentation partner expanded production, ADM joined, and products containing EVERY's protein reached mass retail.
Heura comes next because profitability inside plant-based meat is much harder to achieve than another technical milestone. Vow ranks third on the strength of regulatory approvals, real sales and industrial cultivated-meat production. PARIMA jumps to fourth after its recent 22,000-liter multi-tonne run and two-species regulatory position in Singapore.
Impossible remains a major company, but its current momentum puts it below the fastest-moving startups. Plantible has risen sharply after its new capacity financing. Standing Ovation and Formo lead a deep animal-free dairy group, while Onego is becoming a serious second player in fermented egg protein.
Mission Barns and Wildtype show that cultivated products can already reach consumers when the product and market are chosen carefully. New Culture may have some of the most interesting dairy technology in the group, but its manufacturing still needs to catch up with its casein IP and early demand. Planetary rounds out our list as one of the clearest picks-and-shovels plays on fermentation scaling.
The ranking looks very different from the alternative-protein leaderboard of a few years ago. The companies moving upward now tend to have narrower products, more practical manufacturing plans and much clearer reasons for customers to pay.
| Rank | Startup | Main approach | Why we rank it here today |
|---|---|---|---|
| 1 | The EVERY Company | Precision-fermented egg protein | Strongest combination of demand growth, industrial production and major manufacturing partners |
| 2 | Heura | Plant-based meat and food technology | Positive EBITDA and exceptional product velocity in a difficult category |
| 3 | Vow | Cultivated meat | Multi-country sales, regulatory approvals and large-scale cultivated production |
| 4 | PARIMA | Cultivated duck and chicken | Two-species approval plus a recent multi-tonne 22,000-liter production run |
| 5 | Impossible Foods | Plant-based meat | Huge commercial footprint and strong product velocity, with slower current momentum |
| 6 | Plantible | Plant-derived functional protein | Fresh financing to push annual Rubi Protein capacity above 1,000 metric tons |
| 7 | Standing Ovation | Precision-fermented casein | Industrial validation and strategic backing from both Bel and Danone |
| 8 | Formo | Fermentation-based dairy | Real retail products plus a funded path toward precision-fermented casein |
| 9 | Onego Bio | Precision-fermented egg protein | FDA clearance, 62,000-liter runs and growing industrial partnerships |
| 10 | Mission Barns | Cultivated pork fat | U.S. regulatory clearance and a practical hybrid-product strategy |
| 11 | Wildtype | Cultivated seafood | First FDA-cleared cultivated seafood with growing restaurant distribution |
| 12 | New Culture | Precision-fermented casein | Strong mozzarella IP, early demand and improving product economics |
| 13 | Planetary | Fermentation infrastructure and mycoprotein | Fresh capital, operating infrastructure and a scalable licensing model |
If you want more recent data on this point, please see our latest alternative protein market report.
This chart, featured in our alternative protein market deck, shows how plant-based meat product technology has evolved over time
OUR METHODOLOGY
This analysis asks which alternative protein startups are strongest today. We compare companies across commercial demand, manufacturing progress, regulatory readiness, economics and financing quality rather than treating historical fundraising or name recognition as a proxy for current leadership.
We gave the most weight to recent operating evidence: repeat orders, product velocity, profitability, large production runs, capacity expansion, regulatory clearance, industrial partnerships and financing tied directly to commercialization. Several pieces of evidence pointing in the same direction counted more than one headline milestone.
Recency matters unusually much in this market. Alternative protein has gone through restructurings, shutdowns, insolvencies and major strategy changes, so older funding totals and early technical achievements are used mainly as context. The ranking is built around where companies stand now.
We also use different thresholds for different technologies. Plant-based food, precision fermentation and cultivated meat are at very different stages of commercialization, so a profitability milestone can be decisive for a plant-based company while a repeatable multi-tonne production run or regulatory approval can be much more informative for cultivated meat.
Manufacturing evidence is treated especially carefully. We distinguish between pilot capability, demonstration-scale production, contracted industrial capacity and product already being made repeatedly for customers. Co-manufacturing agreements matter when they materially increase a company's ability to supply real demand.
Regulatory approvals are counted when they enable actual market access, not simply as technical badges. That is why FDA, SFA, FSANZ and related clearances carry more weight when they are followed by restaurant service, retail activity, commercial trials or manufacturing scale-up.
Financing is judged by what it is meant to unlock. Capital for capacity, commercialization or a defined production step is stronger evidence today than another large R&D round with no clear route to repeat sales.
The final ranking is an aggregation of those dimensions rather than a mechanical score. We assessed each company point by point, then looked for the strongest and most consistent combination of recent evidence across demand, production, regulation, economics and financing.
Key sources used for this analysis include The Good Food Institute's alternative-protein investment tracker, The EVERY Company's OvoPro capacity update, Impossible Foods' 2026 leadership-transition disclosure, the European Investment Bank on Formo's €35 million financing, and Standing Ovation's 2026 financing announcement.
For egg and cultivated-protein regulatory and manufacturing claims, we relied on the FDA GRAS record for Onego Bio, Onego Bio's 62,000-liter manufacturing update, the Australian Department of Industry on Vow, Singapore Food Agency's approved novel-food list, and PARIMA's July 2026 production disclosure.
We also used the FDA consultation record for Mission Barns, the FDA cultivated-food record for Wildtype, Plantible's capacity-expansion announcement, and New Culture's primary updates on early mozzarella demand, casein reduction and its additional mozzarella patent.
In our alternative protein market deck, we identify pain points entrepreneurs should prioritize
